Previous close | 15.87 |
Open | 15.95 |
Bid | 14.70 x 800 |
Ask | 14.83 x 800 |
Day's range | 14.80 - 16.04 |
52-week range | 12.95 - 25.47 |
Volume | |
Avg. volume | 852,975 |
Market cap | 1.348B |
Beta (5Y monthly) | 0.85 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.15 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 39.20 |
HAYWARD, Calif., April 09, 2024--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted 12 new employees options to purchase a total of 45,000 shares of the Company’s common stock at an exercise price per share of $16.97, which was the closing price on April 8, 2024, and restri
If you buy and hold a stock for many years, you'd hope to be making a profit. But more than that, you probably want to...
Arcus Biosciences Inc (NYSE:RCUS), a company focused on the discovery, development, and commercialization of cancer immunotherapies, has reported an insider sell according to the latest SEC filings.